Manager × security

Bellevue Group AG VRTX holdings history

Who else holds this security? →

VERTEX PHARMACEUTICALS INC · CUSIP 92532F100 · CIK 1674546

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Bellevue Group AG reported 578.63K VRTX (shares), valued at $287.42M, or 6.05% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
6.05%
Shares
578.63K
578,634
Reported value
$287.42M
USD

Shares decreased 15.14%; reported value decreased 5.61%, and weight changed -1.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20266.05%578,634SEC filing ↗Filed Aug 14, 2026
Q1 20267.25%681,908SEC filing ↗Filed May 15, 2026
Q4 20255.85%681,120SEC filing ↗Filed Feb 17, 2026
Q3 20254.12%505,805SEC filing ↗Filed Nov 14, 2025
Q2 20254.33%441,610SEC filing ↗Filed Aug 14, 2025
Q1 20254.49%413,071SEC filing ↗Filed May 14, 2025
Q4 20243.78%487,434SEC filing ↗Filed Feb 14, 2025
Q3 20244.31%571,406SEC filing ↗Filed Nov 14, 2024
Q2 20244.52%593,461SEC filing ↗Filed Aug 14, 2024
Q1 20244.26%668,750SEC filing ↗Filed May 15, 2024
Q4 20234.58%736,390SEC filing ↗Filed Feb 14, 2024
Q3 20235.62%1,002,735SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20235.62%1,002,735$348.69MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 20234.58%736,390$299.63MShares decreased 26.56%; reported value decreased 14.07%, and weight changed -1.04 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20244.26%668,750$279.54MShares decreased 9.19%; reported value decreased 6.70%, and weight changed -0.32 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20244.52%593,461$278.17MShares decreased 11.26%; reported value decreased 0.49%, and weight changed +0.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20244.31%571,406$265.75MShares decreased 3.72%; reported value decreased 4.46%, and weight changed -0.21 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20243.78%487,434$196.29MShares decreased 14.70%; reported value decreased 26.14%, and weight changed -0.53 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20254.49%413,071$200.27MShares decreased 15.26%; reported value increased 2.03%, and weight changed +0.71 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2025
Q2 20254.33%441,610$196.60MShares increased 6.91%; reported value decreased 1.83%, and weight changed -0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20254.12%505,805$198.09MShares increased 14.54%; reported value increased 0.76%, and weight changed -0.21 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20255.85%681,120$308.79MShares increased 34.66%; reported value increased 55.88%, and weight changed +1.73 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20267.25%681,908$304.50MShares increased 0.12%; reported value decreased 1.39%, and weight changed +1.40 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20266.05%578,634$287.42MShares decreased 15.14%; reported value decreased 5.61%, and weight changed -1.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
Bellevue Group AG · VERTEX PHARMACEUTICALS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1674546","quarter":"2026Q2","cusip":"92532F100"}

get_institutional_manager_history
{"cik":"1674546","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.